<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03851237</url>
  </required_header>
  <id_info>
    <org_study_id>201807099</org_study_id>
    <secondary_id>1R01CA235672-01</secondary_id>
    <nct_id>NCT03851237</nct_id>
  </id_info>
  <brief_title>CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy</brief_title>
  <official_title>Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently there is no clinical biomarker that can be used to select patients for&#xD;
      CCR2-targeted therapy and to monitor response to such therapy. Considering the toxicity and&#xD;
      the rate of response to CCR2-targeted therapy, it is crucial to be able to identify patients&#xD;
      who may not response to this therapy in order to avoid the morbidity and expense associated&#xD;
      with ineffective therapy.&#xD;
&#xD;
      Therefore, the combination of the novel CCR2 imaging agent with the novel CCR2-targeted&#xD;
      therapy in this trial is of great importance to promote science while prolonging the life and&#xD;
      its quality in patients with PDAC. The investigators also believe that this combination will&#xD;
      make substantial contributions to the fields of cancer immunotherapy and tumor&#xD;
      monocyte/macrophage biology. Moreover, this imaging agent has the potential to not only&#xD;
      facilitate development and testing of future CCR2-targeted therapeutic agents but also serve&#xD;
      as a prescreen tool to select appropriate patients for imaging guided treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine whether 64Cu-DOTA-ECL1i detects CCR2 expression in PDAC tumors as measured by direct comparison of visual tumor uptake on 64Cu-DOTA-ECL1i images to CCR2 measurements in surgical specimens</measure>
    <time_frame>Completion of first scan (day 1)</time_frame>
    <description>Visual tumor uptake as compared to background blood/tissue uptake: 1=no uptake, 2=mild uptake, 3=moderate uptake, and 5=striking update&#xD;
Will utilize published methods of immunohistochemical staining techniques</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 1b only: Evaluate whether tumor uptake of 64Cu-DOTA-ECL1i prior to therapy predicts response to standard of care chemotherapy as measured by tumor SUVmax</measure>
    <time_frame>Completion of first scan (day 1)</time_frame>
    <description>SUVmax is a mathematical measurement of tumor burden seen on images and calculated by the following equation SUVmax= r / (a'/w) where r= radioactivity concentration in tumor (kBq/ml) as measured by the PET scanner within a defined region of interest, a'=the decay corrected amount of injected 64Cu-DOTA-ECL1i and w= weight of the patient in grams When PET imaging shows uptake of 64Cu-DOTA-ECL1i in site(s) of known tumor the SUVmax will be compared to clinical measurement of response to treatment taking into consideration standard response criteria including radiological imaging, laboratory values, physical examination and repeat pathology as applicable.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate whether tumor take of 64Cu-DOTA-ECL1i post therapy correlates with CCR2 expression and is predictive of response to therapy as measured by visual tumor uptake on 64Cu-DOTA-ECL1i images</measure>
    <time_frame>Baseline and after 2 cycles of CCR directed therapy (estimated to be 2 months)</time_frame>
    <description>Visual tumor uptake as compared to background blood/tissue uptake: 1=no uptake, 2=mild uptake, 3=moderate uptake, and 5=striking update&#xD;
A decrease in visual tumor uptake from baseline to post therapy imaging in cohort 2 subject is hypothesized to represent response to CCR2 directed therapy while an increase in tumor uptake is expected in cohort 1b subjects who progress while receiving standard therapy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate if tumor take of 64Cu-DOTA-ECL1i is predictive of response to CCR2-directed therapy measured by comparison of SUVmax at imaging prior to the start of CCR2 directed therapy and SUVmax at imaging performed after 2 cycles of CCR2 directed therapy</measure>
    <time_frame>Baseline and after 2 cycles of CCR2 directed therapy (estimated to be 2 months)</time_frame>
    <description>Cohort 2 only&#xD;
SUVmax is a mathematical measurement of tumor burden seen on images and calculated by the following equation SUVmax= r / (a'/w) where r= radioactivity concentration in tumor (kBq/ml) as measured by the PET scanner within a defined region of interest, a'=the decay corrected amount of injected 64Cu-DOTA-ECL1i and w= weight of the patient in grams When PET imaging shows uptake of 64Cu-DOTA-ECL1i in site(s) of known tumor the SUVmax will be evaluated for change at baseline and after 2 cycles of CCR2 directed therapy. SUVmax measurements will also be compared to clinical measurement of response to treatment taking into consideration standard response criteria including radiological imaging, laboratory values, physical examination and repeat pathology as applicable</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1a: Any Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Early-staged localized pancreatic cancer&#xD;
Standard of care diagnostic biopsy&#xD;
64Cu-DOTA-ECL1i-PET/CT imaging - immediately after the dynamic study&#xD;
Receive treatment with upfront surgery such as whipple procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1b: Standard of Care Treatment Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Borderline resectable, locally advanced/metastatic or recurrent pancreatic cancer&#xD;
Standard of care diagnostic biopsy (if available tissue to be used for CCR2 expression)&#xD;
64Cu-DOTA-ECL1i-PET/CT imaging pretherapy&#xD;
Treatment with any standard of care (SOC) chemotherapy&#xD;
Additional 64Cu-DOTA-ECL1i-PET/CT imaging for patients with positive scan at baseline/early therapy at the time of standard of care follow-up imaging appointment --Additional 64Cu-DOTA-ECL1i-PET/CT imaging for patients with negative scan at baseline/early therapy at time recurrence is diagnosed by any standard imaging modality</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: CCR2-Targeted Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Locally advanced or borderline resectable pancreatic cancer&#xD;
Biopsy per therapeutic protocol (if available tissue to be used for CCR2 expression)&#xD;
64Cu-DOTA-ECL1i-PET/CT imaging pretherapy&#xD;
2 cycles of CCR2-targeted therapy&#xD;
Biopsy per therapeutic protocol (tissue to be used for CCR2 expression) --Additional 64Cu-DOTA-ECL1i-PET/CT imaging after 2 cycles of therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>64Cu-DOTA-ECLIi</intervention_name>
    <description>-The first four patients enrolled on study will undergo an additional delayed imaging time point approximately 2-6 hours following 64Cu-DOTA-ECL1i</description>
    <arm_group_label>Cohort 1a: Any Treatment Group</arm_group_label>
    <arm_group_label>Cohort 1b: Standard of Care Treatment Chemotherapy</arm_group_label>
    <arm_group_label>Cohort 2: CCR2-Targeted Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET/CT</intervention_name>
    <description>-Standard of care</description>
    <arm_group_label>Cohort 1a: Any Treatment Group</arm_group_label>
    <arm_group_label>Cohort 1b: Standard of Care Treatment Chemotherapy</arm_group_label>
    <arm_group_label>Cohort 2: CCR2-Targeted Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients 18 years of age or older with:&#xD;
&#xD;
               -  newly diagnosed early-staged localized pancreatic ductal adenocarcinoma (PDAC)&#xD;
                  scheduled to undergo Whipple procedure (cohort 1a) OR&#xD;
&#xD;
               -  borderline resectable, locally advanced, metastatic, or recurrent PDAC (cohort&#xD;
                  1b) scheduled to undergo chemotherapy OR&#xD;
&#xD;
               -  borderline resectable, locally advanced PDAC (cohort 2) who is eligible and / or&#xD;
                  signed consent to undergo CCR2-targeted therapy example:[(phase 1/2 clinical&#xD;
                  trial combining an oral CCR2/5i (BMS-813160) with chemotherapy (gemcitabine plus&#xD;
                  nab-paclitaxel) and anti-PD-1 (nivolumab), PI, Dr. Kian Lim) HRPO #201806007] AND&#xD;
&#xD;
               -  at least one measurable [defined as lesions that can be accurately measured in at&#xD;
                  least one dimension (longest diameter to be recorded) as â‰¥ 10 mm with CT scan or&#xD;
                  MRI] A cohort 1B subject who has been previously treated for PDAC with a&#xD;
                  diagnosis of recurrence and a lesion size of 1.5 cm or greater will be allowed to&#xD;
                  enroll before institution of therapy or within 20 days after starting a 2nd line&#xD;
                  or later (new therapy) for recurrent disease.&#xD;
&#xD;
          -  Able to give informed consent&#xD;
&#xD;
          -  Not currently pregnant or nursing: Subject must be surgically sterile (has had a&#xD;
             documented bilateral oophorectomy and/or documented hysterectomy), post-menopausal&#xD;
             (cessation of menses for more than 1 year), non-lactating, or of childbearing&#xD;
             potential for whom a urine pregnancy test (with the test performed within the 24 hour&#xD;
             period immediately prior to administration of 64Cu-DOTA-ECL1i) is negative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with other invasive malignancies, with the exception of non-melanoma skin&#xD;
             cancer, who had (or have) any evidence of the other cancer present within the last 5&#xD;
             years&#xD;
&#xD;
          -  Unable to tolerate up to 90 min of PET/CT imaging per imaging session.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farrokh Dehdashti, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Farrokh Dehdashti, M.D.</last_name>
    <phone>314-362-1474</phone>
    <email>dehdashtif@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farrokh Dehdashti, M.D.</last_name>
      <phone>314-362-1474</phone>
      <email>dehdashtif@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Farrokh Dehdashti, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kian-Huat Lim, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yongjian Liu, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marianna Ruzinova, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Richard Laforest, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Hawkins, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amber Salter, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2019</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

